- Home
- SLS vs NMRA Comparison
SLS vs NMRA Comparison
Compare SLS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLS | NMRA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.7M | 576.1M |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SLS | NMRA |
|---|---|---|
| Price | $5.92 | $3.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.7M |
| Earning Date | 04-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.69 | 57.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $0.62 |
| 52 Week High | $5.66 | $3.65 |
Technical Indicators
Market Signals| Indicator | SLS | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 74.63 | 58.83 |
| Support Level | $1.48 | $1.78 |
| Resistance Level | N/A | $3.25 |
| Average True Range (ATR) | 0.50 | 0.21 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 93.19 | 51.12 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.